According to CoherentMI, The metastatic triple-negative breast cancer (mTNBC) market is estimated to be valued at USD 1.65.2 Bn in 2025 and is expected to reach USD 2.35.2 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.2% from 2025 to 2032. Key Takeaways https://timessquarereporter.com/news/metastatic-triple-negative-breast-cancer--mtnbc--market-propelled-by-targeted-therapies